Related references
Note: Only part of the references are listed.Ubrogepant for the treatment of migraine
Martina Curto et al.
EXPERT OPINION ON PHARMACOTHERAPY (2020)
Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition
Hans-Christoph Diener et al.
CEPHALALGIA (2019)
Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
Valery L. Feigin et al.
LANCET NEUROLOGY (2019)
Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine
Peter J. Goadsby et al.
BRAIN (2019)
Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial
Robert Croop et al.
LANCET (2019)
Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine
Richard B. Lipton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN)
Li Shen Loo et al.
BMC NEUROLOGY (2019)
Why is the therapeutic effect of acute antimigraine drugs delayed? A review of controlled trials and hypotheses about the delay of effect
Peer Tfelt-Hansen et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Recent Advances in Pharmacotherapy for Episodic Migraine
Calvin Chan et al.
CNS DRUGS (2019)
Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine The ACHIEVE II Randomized Clinical Trial
Richard B. Lipton et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
The Emperor's New Gepants: Are the Effects of the New Oral CGRP Antagonists Clinically Meaningful?
Peer Tfelt-Hansen et al.
HEADACHE (2019)
Ubrogepant for the Treatment of Migraine
David W. Dodick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition
Jes Olesen
CEPHALALGIA (2018)
Poor medical care for people with migraine in Europe - evidence from the Eurolight study
Zaza Katsarava et al.
JOURNAL OF HEADACHE AND PAIN (2018)
CGRP as the target of new migraine therapies - successful translation from bench to clinic
Lars Edvinsson et al.
NATURE REVIEWS NEUROLOGY (2018)
Targeted 5-HT1F Therapies for Migraine
Marta Vila-Pueyo
NEUROTHERAPEUTICS (2018)
Emerging drugs for migraine treatment: an update
Giorgio Lambru et al.
EXPERT OPINION ON EMERGING DRUGS (2018)
Lasmiditan is an effective acute treatment for migraine A phase 3 randomized study
Bernice Kuca et al.
NEUROLOGY (2018)
Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice
Jessica C. Oswald et al.
JOURNAL OF PAIN RESEARCH (2018)
Delayed absorption of many (paracetamol, aspirin, other NSAIDs and zolmitriptan) but not all (sumatriptan, rizatriptan) drugs during migraine attacks and most likely normal gastric emptying outside attacks. A review
Peer Carsten Tfelt-Hansen
CEPHALALGIA (2017)
Migraine affects 1 in 10 people worldwide featuring recent rise: A systematic review and meta-analysis of community-based studies involving 6 million participants
Yohannes W. Woldeamanuel et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2017)
PATHOPHYSIOLOGY OF MIGRAINE: A DISORDER OF SENSORY PROCESSING
Peter J. Goadsby et al.
PHYSIOLOGICAL REVIEWS (2017)
The Evidence for Prescription Information for Possible Use of a Repeated Dose of Oral Triptans: A Comment
Peer Tfelt-Hansen et al.
HEADACHE (2016)
Medication overuse headache in Europe and Latin America: general demographic and clinical characteristics, referral pathways and national distribution of painkillers in a descriptive, multinational, multicenter study
Ninett Louise Find et al.
JOURNAL OF HEADACHE AND PAIN (2016)
GBD 2015: migraine is the third cause of disability in under 50s
Timothy J. Steiner et al.
JOURNAL OF HEADACHE AND PAIN (2016)
Introduction to the Guideline, and General Principles of Acute Migraine Management
Irene Worthington et al.
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES (2016)
Medication-overuse headache: a perspective review
Maria Lurenda Westergaard et al.
THERAPEUTIC ADVANCES IN DRUG SAFETY (2016)
Triptan-induced disruption of trigemino-cortical connectivity
Inga L. Kroeger et al.
NEUROLOGY (2015)
Targeted Review: Medications for Acute Migraine Treatment
Irene Worthington et al.
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES (2014)
Pharmacological Acute Migraine Treatment Strategies: Choosing the Right Drug for a Specific Patient
Irene Worthington et al.
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES (2014)
What Do Patients Consider to Be the Most Important Outcomes for Effectiveness Studies on Migraine Treatment? Results of a Delphi Study
Antonia F. H. Smelt et al.
PLOS ONE (2014)
Relatively slow and long-lasting antimigraine effect of dihydroergotamine is most likely due to basic pharmacological attributes of the drug: A review
Peer C. Tfelt-Hansen
CEPHALALGIA (2013)
Sustained pain relief with dihydroergotamine in migraine is potentially due to persistent binding to 5-HT1B and 5-HT1D receptors
S. Kori et al.
JOURNAL OF HEADACHE AND PAIN (2013)
Migraine pathophysiology: Anatomy of the trigeminovascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain
Rodrigo Noseda et al.
PAIN (2013)
Frovatriptan A Review of its Use in the Acute Treatment of Migraine
Mark Sanford
CNS DRUGS (2012)
Factors Associated With Triptan Use in Episodic Migraine: Results From the American Migraine Prevalence and Prevention Study
Min Kyung Chu et al.
HEADACHE (2012)
Hydrophilic anti-migraine triptans are substrates for OATP1A2, a transporter expressed at human blood-brain barrier
Ziqiang Cheng et al.
XENOBIOTICA (2012)
MAP0004, Orally Inhaled DHE: A Randomized, Controlled Study in the Acute Treatment of Migraine
Sheena K. Aurora et al.
HEADACHE (2011)
Published and not fully published double-blind, randomised, controlled trials with oral naratriptan in the treatment of migraine: a review based on the GSK Trial Register
Peer Carsten Tfelt-Hansen
JOURNAL OF HEADACHE AND PAIN (2011)
Preclinical pharmacological profile of the selective 5-HTIF receptor agonist lasmiditan
David L. Nelson et al.
CEPHALALGIA (2010)
Distinct Pharmacokinetic Profile and Safety of a Fixed-Dose Tablet of Sumatriptan and Naproxen Sodium for the Acute Treatment of Migraine
Lynda J. Haberer et al.
HEADACHE (2010)
CGRP Receptor Antagonism and Migraine
Lars Edvinsson et al.
NEUROTHERAPEUTICS (2010)
What can be learned from the history of recurrence in migraine? A comment
Peer Tfelt-Hansen
JOURNAL OF HEADACHE AND PAIN (2009)
Unpublished clinical trials with sumatriptan
Peer Carsten Tfelt-Hansen
LANCET (2009)
Early vs. non-early intervention in acute migraine - 'Act when Mild (AwM)'. A double-blind, placebo-controlled trial of almotriptan
P. J. Goadsby et al.
CEPHALALGIA (2008)
Pathways to the best fit of triptans for migraine patients
M. G. Buzzi
CEPHALALGIA (2008)
Efficacy and safety of 1,000mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms
C. Lampl et al.
JOURNAL OF NEUROLOGY (2007)
Sumatriptan-naproxen for acute treatment of migraine - A randomized trial
Jan Lewis Brandes et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Eletriptan - A review of its use in the acute treatment of migraine
Paul L. McCormack et al.
DRUGS (2006)
Early intervention in migraine with sumatriptan tablets 50 mg versus 100 mg: A pooled analysis of data from six clinical trials
P Winner et al.
CLINICAL THERAPEUTICS (2005)
Triptan-induced contractile (5-HT1B receptor) responses in human cerebral and coronary arteries:: relationship to clinical effect
L Edvinsson et al.
CLINICAL SCIENCE (2005)
An assessment of the burden of migraine using the willingness to pay model
SW Hamelsky et al.
CEPHALALGIA (2005)
Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine - A randomised, double-blind, placebo-controlled study
D Dodick et al.
CNS DRUGS (2005)
Calcitonin gene-related peptide receptor antagonist BIBN4096BS for the acute treatment of migraine
J Olesen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Naratriptan for the treatment of acute migraine: meta-analysis of randomised controlled trials
DM Ashcroft et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2004)
Defeating migraine pain with triptans: A race against the development of cutaneous allodynia
R Burstein et al.
ANNALS OF NEUROLOGY (2004)
Triptans and CNS side-effects: pharmacokinetic and metabolic mechanisms
DW Dodick et al.
CEPHALALGIA (2004)
Speed of onset and zolmitriptan nasal efficacy of spray in the acute treatment of migraine - A randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet
BR Charlesworth et al.
CNS DRUGS (2003)
Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine
S Christie et al.
EUROPEAN NEUROLOGY (2003)
Preliminary studies of the pharmacokinetics and tolerability of zolmitriptan nasal spray in healthy volunteers
R Yates et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Triptans (serotonin, 5-HT1B/1D agonists) in migraine:: detailed results and methods of a meta-analysis of 53 trials
MD Ferrari et al.
CEPHALALGIA (2002)
What do patients with migraine want from acute migraine treatment?
RB Lipton et al.
HEADACHE (2002)
Almotriptan - A review of its use in migraine
SJ Keam et al.
DRUGS (2002)
Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot (R)) in the acute treatment of migraine: A multicentre, randomised, double-blind, placebo-controlled comparison
HC Diener et al.
EUROPEAN NEUROLOGY (2002)
Meta-analysis of rizatriptan efficacy in randomized controlled clinical trials
MD Ferrari et al.
CEPHALALGIA (2001)
Triptans in migraine - A comparative review of pharmacology, pharmacokinetics and efficacy
P Tfelt-Hansen et al.
DRUGS (2000)
Treatment of mild headache in disabled migraine sufferers: Results of the spectrum study
RK Cady et al.
HEADACHE (2000)
Effect of early intervention with sumatriptan on migraine pain: Retrospective analyses of data from three clinical trials
RK Cady et al.
CLINICAL THERAPEUTICS (2000)
Ergotamine in the acute treatment of migraine - A review and European consensus
P Tfelt-Hansen et al.
BRAIN (2000)
Share Paper
